UNSPSC 51151541: Galantamine hydrobromide

This classification denotes an acetylcholinesterase inhibitor with the molecular formula C17H21NO3.BrH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier MJ4PTD2VVW, chemically known as 1,2,3,4,6,7,7a,11c-octahydro-9-methoxy-2-methyl-benzofuro(4,3,2-efg)(2)benzazocin-6-ol hbr but more generally known as galantamine hydrobromide, which bears US NIH Compound Identifier 121587. European Medicines Agency schedules Galantamine hydrobromide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02301MIG.

UNSPSC 51151541 Galantamine hydrobromide is a Commodity code that nominally describes a specific pharmaceutical compound, but recent state and local solicitations tagged under this code show little alignment with that narrow scope. The Seminole County, Florida IFB60459723LAS opportunity, posted June 30, 2026, sought procurement of naloxone and drug deactivation systems — not galantamine — through competitive bidding for quarterly delivery to the county's community health facility. The Texas Health and Human Services Commission's RFI HHS0017013, issued April 3, 2026, explored direct-to-manufacturer prescription fulfillment capabilities across a broad range of pharmaceutical products and distribution models, again without specific reference to galantamine. Both solicitations address pharmaceutical procurement and opioid-response initiatives at the state and county level, but neither targets galantamine specifically, suggesting the code may be misapplied or that galantamine procurement through state and local channels is negligible relative to broader pharmaceutical initiatives.

Recent activity under this code is limited geographically to Florida and Texas, with no additional state or local opportunities evident in the source block. The issuing bodies are a county health department (Seminole County) handling direct product procurement and a state health agency (Texas HHS Commission) exploring pharmacy benefit program architecture. The mismatch between the code's nominal scope and the actual work being solicited — naloxone distribution, drug deactivation, and pharmacy benefit network restructuring — indicates this code shows little relevant recent activity for firms focusing on galantamine supply. Firms pursuing pharmaceutical procurement at the state and local level should monitor broader pharmaceutical and drug-abuse-response categories rather than rely on this specific commodity code for market intelligence.